Deltex Medical Regulatory News (DEMG)

3 Jan 2007 07:00

Deltex Medical Group PLC03 January 2007 Deltex Medical Group plc CardioQTM reported as beneficial in high risk surgery on children 3 January 2007 Deltex Medical Group plc ('Deltex Medical' or the 'Company'), theUK's leading haemodynamic monitoring company, announces the publication by aspecialist medical journal of case studies from Royal Manchester Children'sHospital on using CardioQ during a high risk surgical procedure on children. Both case studies focus on the use of the CardioQ during surgery to removepheochromocytoma, a rare but dangerous tumour affecting the adrenal glands. The case reports, published in Pediatric Anesthesia 2006 (Volume 16: Issue 8,pages 867-876) state that the CardioQ (or 'ODM') was selected because: "its usein pediatric practice is growing as there is a wider appreciation of theinformation it can provide together with its excellent safety record". The paperconcludes that: "The ODM provides the anesthetist with continuous beat to beat observation ofthe patient's circulatory status. Measured variables such as FTc (Flow TimeCorrected) and PV (Peak Velocity) combined with derived variables such as strokevolume (SV) and cardiac output (CO), together with information gained fromelsewhere such as direct arterial and central venous pressures, allow theanesthetist to react rapidly to the often sudden and profound hemodynamicchanges seen during the resection of a pheochromocytoma. The additionalinformation provided may allow a more appropriate and specific choice of therapyat often crucial times in management. This may be especially relevant in casesof preexisting comorbidity where the wrong choice of agent may have particularlydeleterious effects". The abstract of the article together with the full text (available tosubscribers only) can be seen at http://www.blackwell-synergy.com/toc/pan/16/8. Deltex Medical's chief executive, Andy Hill, commented: "These case reports demonstrate a new, previously unreported, clinicalapplication for our technology. The benefits which make oesophageal Dopplermonitoring with the CardioQ of value in treating this rare condition are thesame as those in far more common applications for both children and adults: itis safe, easy to use and a far more sensitive and accurate monitor of changethan any other haemodynamic monitoring technology, allowing the doctor tointervene earlier and with more confidence than ever before". For further information, please contact:- Deltex Medical Group plc 01243 774 837Nigel Keen, Chairman nk@deltexmedical.comAndy Hill, Chief Executive ah@deltexmedical.comEwan Phillips, Finance Director ep@deltexmedical.com Gavin Anderson & Company 020 7554 1400Marie Cairney mcairney@gavinanderson.co.uk Charles Stanley Securities 020 7149 6457Philip Davies philip.davies@csysecurities.com Notes for Editors Deltex Medical manufactures and markets the CardioQ monitor, which usesdisposable ultra-sound probes inserted into the oesophagus to determine theamount of blood being pumped around the body - 'circulating blood volume'.Reduced circulating blood volume is known as hypovolaemia, which leads toinsufficient oxygen being delivered to the organs. This causes medicalcomplications including peripheral and major organ failure which can lead todeath. Hypovolaemia, which is akin to severe dehydration, affects virtuallyevery patient having surgery because of the combined effects of pre-operativestarvation, the impact of the anaesthetic agents and trauma from the surgeryitself. Using fluids and drugs, guided by the CardioQ, to optimise the amount ofcirculating blood significantly reduces post-operative complications allowingpatients to make a faster, more complete recovery and return home earlier. The CardioQ incorporates the Company's proprietary software and a smalldiameter, easy-to-use, minimally invasive, disposable oesophageal probe that isused for transmitting and receiving an ultra-sound signal. By using thistechnology, the CardioQ provides clinicians with the ability to haemodynamicallyoptimise critically ill patients and those undergoing routine moderate to majorsurgery through the controlled administration of fluid and drugs. Haemodynamicoptimisation has been scientifically proven to improve the speed and quality ofpatient recovery and reduce hospital stay. There are already over 1,250 CardioQs currently in use in hospitals worldwideand distribution arrangements are in place in over 30 countries. In addition,there are currently more than 90 clinical publications on the use of the CardioQwhich have repeatedly:- • Validated the results of the Monitor against known standards for measuring cardiac output, demonstrating that the technology works • Proved that the CardioQ works in a wide range of surgical procedures • Demonstrated that the Company's technology provides significant health and economic benefits by helping to reduce post-operative complications and length of hospital stays by an average of 30 to 40 per cent for a wide range of patients. This information is provided by RNS The company news service from the London Stock Exchange